naperiglipron

Naperiglipron is an investigational, orally available, non‑peptide small‑molecule agonist of the glucagon‑like peptide‑1 receptor (GLP‑1R) being developed by Eli Lilly for the treatment of obesity and type 2 diabetes. It selectively activates GLP‑1R to enhance glucose‑dependent insulin secretion, lower blood glucose, and suppress appetite, aiming to deliver GLP‑class metabolic and weight‑loss benefits in a once‑daily oral format.[1][4][6][8][9][10][11] The program is in mid‑stage clinical development, with phase 2 studies in obesity and type 2 diabetes and additional phase 1 trials in Japanese and Chinese participants, although two phase 2 trials were recently terminated for strategic business reasons while another phase 2 obesity trial continues.[1][2][6][8][9]